Form 4: Teva Pharmaceutical Industries Executive Acquires Restricted Share Units
SEC Form 4 Filing
Placid Jover, Executive Vice President and Chief Human Resources Officer at Teva Pharmaceutical Industries, was granted 56,603 restricted share units on March 5, 2025, according to a Form 4 filing.
Summary
- Placid Jover, an executive at Teva Pharmaceutical Industries, received 56,603 restricted share units on March 5, 2025.
- These units will vest in installments over four years, starting March 5, 2026.
- Each restricted share unit represents the right to receive one ordinary share or its cash value.
- The filing was submitted on March 7, 2025.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to executive compensation, and does not contain any information that would significantly impact investor sentiment positively or negatively.
Positives
- The grant of restricted share units aligns the executive's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Industry Context
Executive compensation through equity grants is a common practice in the pharmaceutical industry to incentivize performance and align management interests with shareholder value. These grants are typically structured with vesting schedules to encourage long-term commitment.
Comparison to Industry Standards
- Companies like Pfizer, Johnson & Johnson, and Novartis also utilize restricted stock units as part of their executive compensation packages.
- The vesting schedules for these grants typically range from three to five years, aligning with Teva's four-year vesting schedule.
- The size of the grant is generally determined based on the executive's role, performance, and the company's overall compensation strategy.
Stakeholder Impact
- Shareholders may view the equity grant as a positive sign, aligning executive interests with long-term company performance.
- Employees may see the grant as a reflection of the company's commitment to rewarding its executives.
Key Dates
| Date | Description |
|---|---|
| 03/05/2025 | Date of restricted share units grant |
| 03/05/2026 | First vesting date for 14,150 restricted share units |
| 03/05/2027 | Second vesting date for 14,150 restricted share units |
| 03/05/2028 | Third vesting date for 14,150 restricted share units |
| 03/05/2029 | Final vesting date for 14,153 restricted share units |
| 03/07/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.